Continuing Medical Education (CME): Flawed JAMA Report Blurs Line Between “Medical Communication Companies” and Accredited “Medical Education Companies”
Today, the Journal of the American Medical Association (JAMA) published a brief report (Medical Communication Companies and Industry Grants) as well as an editorial in order to explore "the financial relationships between MCCs and drug device companies." The authors use a mixture of outdated figures, hyperbole, and blatant untruths to piece together their articles, which, according to CME Coalition Senior Advisor, Andrew Rosenberg, contain "so many inaccuracies and examples of unfounded innuendo" that "it is a challenge to enumerate them all."
JAMA has decided not to make the report available to the public, but we have compiled the report's content.
JAMA erroneously interchanges Medical Communication Companies with Medical Education Companies:
Grant Donations 2010
Roche/Genentech
106,916,052
Merck
99,481,044
Pfizer
89,520,722
Abbott
69,518,593
Eli Lilly
54,767,686
Bristol-Myers Squibb
43,570,166
Amgen
43,383,578
AstraZeneca
35,628,747
Sanofi-Aventis
34,404,149
GlaxoSmithKline
29,658,381
Medtronic
26,125,342
Astellas
11,905,202
Forest Laboratories
9,400,372
Shire
3,987,736
Total*
658,267,770
Note the JAMA Article has the total of 657,643,322 – excel addition did not mat...
Source: Policy and Medicine - Category: Health Medicine and Bioethics Commentators Authors: Thomas Sullivan Source Type: blogs
More News: Academia | Advertising | Cancer | Cancer & Oncology | Computers | Continuing Medical Education | Education | Environmental Health | Gabapentin | Grants | Health | Health Management | Health Medicine & Bioethics Commentators | Infectious Diseases | Internet | Learning | Legislation | Men | Neurology | Neurontin | Neuroscience | Nurses | Nursing | Primary Care | Science | Study | Substance Abuse | Training | Universities & Medical Training | Websites